### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# <u>Materials</u>

Antibodies	Yes (indicate where provided: page no/section/legend)	n/a
For commercial reagents, provide supplier		Χ
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: page no/section/legend)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		X
Primary cultures: Provide species, strain, sex of		Χ
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: page no/section/legend)	n/a
Laboratory animals: Provide species, strain, sex, age,		Χ
genetic modification status. Provide accession		
number in repository <b>OR</b> supplier name, catalog		
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the		Χ
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		Χ
in repository (where relevant) OR RRID		

Plants and microbes	Yes (indicate where provided: page no/section/legend)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		X
<b>Microbes:</b> provide species and strain, unique accession number if available, and source		Х

Human research participants	Yes (indicate where provided: page no/section/legend)	n/a
Identify authority granting ethics approval (IRB or		Χ
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent		Χ
obtained from study participants.		
Report on age and sex for all study participants.		Χ

# Design

Study protocol	Yes (indicate where provided: page no/section/legend)	n/a
For clinical trials, provide the trial registration		Х
number <b>OR</b> cite DOI in manuscript.		

Laboratory protocol	Yes (indicate where provided: page no/section/legend)	n/a
Provide DOI or other citation details if detailed step-		Х
by-step protocols are available.		

Experimental study design (statistics details)	Yes (indicate where provided: page no/section/legend)	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination		Х
Randomisation		Х
Blinding		Х
Inclusion/exclusion criteria		Х

Sample definition and in-laboratory replication	Yes (indicate where provided: page no/section/legend)	n/a
State number of times the experiment was replicated in laboratory		Х
Define whether data describe technical or biological replicates		Х

Ethics	Yes (indicate where provided: page no/section/legend)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Х
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Х
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		Х

Dual Use Research of Concern (DURC)	Yes (indicate where provided: page no/section/legend)	n/a
If study is subject to dual use research of concern,		Х
state the authority granting approval and reference		
number for the regulatory approval		

#### **Analysis**

Attrition	Yes (indicate where provided: page no/section/legend)	n/a
State if sample or data point from the analysis is	By cleaning the DNA sequence data that was	
excluded, and whether the criteria for exclusion were	downloaded from the NCBI public database, we	
determined and specified in advance.	excluded 1618 sequences (main text, Methods, section	
	'DNA sequence alignment, gene trees, and error-	
	checking').	
Statistics	Yes (indicate where provided: page no/section/legend)	n/a
Describe statistical tests used and justify choice of	A range of phylogenetic analyses were conducted (see	
tests.	Methods for details)	
Data Availability	V 1. P	,
Data Availability	Yes (indicate where provided: page no/section/legend)	n/a
State whether newly created datasets are available,	Yes, all data from the credible sets of phylogenies are	
including protocols for access or restriction on	available at <a href="http://vertlife.org/phylosubsets">http://vertlife.org/phylosubsets</a> , and on	
access.	Dryad at https://doi.org/10.5061/dryad.tb03d03	
If data are publicly available, provide accession	Data from the credible sets of phylogenies are available	
number in repository or DOI or URL.	at <a href="http://vertlife.org/phylosubsets">http://vertlife.org/phylosubsets</a> , and on Dryad at	
	https://doi.org/10.5061/dryad.tb03d03	
If publicly available data are reused, provide	All NCBI accession numbers are also provided in S1	
accession number in repository or DOI or URL, where	Data, file '31-gene_DNA-sampling.xlsx' on Dryad:	
possible.	https://doi.org/10.5061/dryad.tb03d03	
Code Availability	Yes (indicate where provided: page no/section/legend)	n/a
For all newly generated code and software essential	The transfer of the state of th	,
for replicating the main findings of the study:		
State whether the code or software is available.	Yes, all code is available in S8 Data on Dryad	
	https://doi.org/10.5061/dryad.tb03d03 and on	
	https://github.com/n8upham/MamPhy_v1	
If code is publicly available, provide accession	Yes, all code is available in S8 Data on Dryad	
number in repository, or DOI or URL.	https://doi.org/10.5061/dryad.tb03d03 and on	

#### Reporting

Adherence to community standards	Yes (indicate where provided: page no/section/legend)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,		X
ARRIVE) have been followed, and whether a checklist		
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		